For example, MAPK inhibition in different types of cancer cells addicted to mutant KRAS or RTKs, such as EGFR (NSCLC), HER2 (breast cancer) or ALK (neuroblastoma), can provoke an increase in the secretion of fibroblast growth factor and interleukin-6. This evidence concerns the gene EGFR and non-small cell lung carcinoma.